Evidence map›Paper›PMID 39599743›Full record

Trial reportNutrients2024

Low-Dose Ketone Monoester Administration in Adults with Cystic Fibrosis: A Pilot and Feasibility Study.

Eric P Plaisance, Jonathan M Bergeron, Mickey L Bolyard, Heather Y Hathorne, Christina M Graziano, Anastasia Hartzes, Kristopher R Genschmer, Jessica A Alvarez, Amy M Goss, Amit Gaggar and 1 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Eric P PlaisanceDepartment of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0001-9621-6583
Jonathan M BergeronDivision of Pulmonary, Allergy, & Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0009-0001-5340-5218
Mickey L BolyardDepartment of Health & Kinesiology, University of Utah, Salt Lake City, UT 84112, USA.ORCID 0000-0003-4541-0372
Heather Y HathorneDivision of Pulmonary, Allergy, & Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Christina M GrazianoDepartment of Human Studies, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0009-0009-6586-3548
Anastasia HartzesDepartment of Biostatistics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Kristopher R GenschmerDivision of Pulmonary, Allergy, & Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0002-1836-9522
Jessica A AlvarezDivision of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University, Atlanta, GA 30322, USA.
Amy M GossDepartment of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0001-8772-2935
Amit GaggarDivision of Pulmonary, Allergy, & Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0003-1586-5632
Kevin R FontaineDepartment of Health Behavior, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

Funding

Why is the prevalence of obesity so high in U.S. Southern States? Regional predictors of BMI and obesity treatment response.P30DK056336 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BARBARA A GOWER · 2000 to 2026
$31.9M
UAB CF Research and Translation Core CenterP30DK072482 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AMIT GAGGAR · 2007 to 2026
$23.0M
NIDDK NIH HHS P30 DK056336NIDDK NIH HHS P30 DK072482NIH HHS 1P30DK072482-20A1
6 · The paper itself

Abstract

introductionCystic fibrosis transmembrane conductance regulator (

methodsFourteen participants receiving modulator therapy were randomized to receive either KME (n = 9) or placebo control (PC, n = 5) for 5-7 days during hospitalization for treatment of acute pulmonary exacerbation or as outpatients under standard care.

resultsThe KME was well tolerated, with only mild reports of gastrointestinal distress. D-βHB concentrations increased from 0.2 ± 0.1 mM to 1.6 ± 0.6 mM in the KME group compared to 0.2 ± 0.0 to 0.3 ± 0.1 in the PC group (

conclusionsWith the emerging role of exogenous ketones as nutrient signaling molecules and mediators of metabolism, we showed that KME is well tolerated, increases circulating D-βHB concentrations, and produces outcomes that justify the need for large-scale clinical trials to investigate the role of KME on whole-body and tissue lipid accumulation and inflammation in pwCF.

Indexed as

Cystic FibrosisFeasibility StudiesKetonesQuality of Life3-Hydroxybutyric AcidAdultAnti-Inflammatory AgentsBiomarkersCystic Fibrosis Transmembrane Conductance RegulatorDouble-Blind MethodEstersFemaleHumansInflammationMalePilot Projects3-Hydroxybutyric AcidAnti-Inflammatory AgentsBiomarkersCystic Fibrosis Transmembrane Conductance RegulatorEstersKetonesinflammationketogenic dietketoneslow-carbohydrate dietpulmonary function

Identifiers

PMID39599743
PMCPMC11597165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.